ERSP deflates Leading Edge's enhancement claims
This article was originally published in The Tan Sheet
Executive Summary
The Electronic Retailing Self-Regulation Program recommends Leading Edge Marketing modify or discontinue some efficacy claims for its male enhancement products. ERSP in a Sept. 15 report also recommends Leading Edge disclose more clearly on its BetterSexMall.com website the relationship between the products, reviewers and the firm. Following an anonymous challenge, ERSP recommends the company modify claims related to stamina, erection size and "more powerful orgasm" for its products VigRX, VigRX Plus and VigRX Oil. No human studies were conducted with the products, and Leading Edge's data did not adequately support the claims, says the Council of Better Business Bureaus division. ERSP notes the Earth City, Mo.-based firm modified its website, but did not adequately disclose that it owns BetterSexMall.com, which purports to be independent. ERSP notes three Leading Edge-affiliated websites with customer testimonials do not comply with 2009 Federal Trade Commission guideline requirement to disclose typical results from use of the product (1"The Tan Sheet" Oct. 12, 2009). The company said it plans to comply
You may also be interested in...
FTC Testimonial Guide Moves Past "Results Not Typical," Enters Blog Era
The Federal Trade Commission raised the bar on substantiation and disclosure of "typical results" in testimonials and endorsements in advertising, in a revised guide released Oct. 5
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.